SARAH WOODFIELD to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications SARAH WOODFIELD has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.295
-
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
Score: 0.139
-
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
Score: 0.097
-
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Cancer Lett. 2017 08 01; 400:61-68.
Score: 0.021
-
Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget. 2017 Jan 03; 8(1):1555-1568.
Score: 0.021
-
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol. 2015 Nov; 76(5):977-87.
Score: 0.019